Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
about
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencingClinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian populationDetection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differencesBreast cancer, dermatofibromas and arsenic.Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic reviewPrevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancerPoly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data.Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.BRCA2 variants and cardiovascular disease in a multi-ethnic study.High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.The geographic distribution of melanoma incidence in Massachusetts, adjusted for covariates.Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancerBRCA1/2 genetic testing uptake and psychosocial outcomes in men.The construction of common and specific significance subnetworks of Alzheimer's disease from multiple brain regions.Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.Interest in genomic SNP testing for prostate cancer risk: a pilot survey.Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian populationRisk of second primary cancer in men with breast cancerGenetics of breast cancer: a topic in evolution.Assessing breast cancer risk: genetic factors are not the whole story.Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations.Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome SequencingIdentification, genetic testing, and management of hereditary melanoma.Identification of a novel NBN truncating mutation in a family with hereditary prostate cancerPrecursors to pancreatic cancer.Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes.Clinical significance of large rearrangements in BRCA1 and BRCA2.Cancer risks among BRCA1 and BRCA2 mutation carriers.
P2860
Q26991615-E92355DD-4C41-4CF7-B401-F52CA0A34CFCQ30361333-797DC8AA-2322-413C-B12C-E1B3E45FDAFFQ30875021-56F2E150-5001-48B2-913E-C12A5BD2EFD4Q33246295-0918E7D1-5101-448F-81F5-C5E53F603961Q33296526-A160E98B-F3FC-4F48-BAEC-579E200B9844Q33484437-AAC4A1B0-6660-4879-8EDF-7DC4723E62CBQ33555632-BBABBD6E-BC8B-4D65-894F-054BD0A7A110Q33567864-AB23442E-FD88-4300-B3DA-9040B0AE0DA2Q33594181-4B388581-138C-4F04-8741-EDABF3446552Q33639057-D3AABFC0-F916-4BD9-872D-EECFBC10C685Q33851843-ED4E983F-2638-406E-A9DF-C2F2E9812D33Q33881971-A6F317B9-CF87-4C07-9681-05CE5EA53817Q34146866-77DCC71D-774F-4C64-B23C-15A853AD2E2CQ34305493-135AFA35-615F-4D15-8C32-B524D6ED5C9DQ34319541-D9555159-DBE8-4F8A-8D94-415A7E5C77CDQ34342912-E8E77724-9772-4E54-9D96-CC8958B9B37AQ34433513-59CCF1DC-0666-4DBD-B9BD-314525DE595CQ34589804-36F792DA-CA1E-45E0-9BF6-23EFE9D105A9Q34838226-E57B4381-CE81-4C98-AF0F-6C0AB24755AFQ35012599-76D3362F-9DDF-4107-A5F9-F8C99ED482A2Q35019634-6D9D9DF5-EBC0-46F8-976D-8D2FB6F08415Q35020974-87862A22-B2EC-4746-A723-B1F09F375057Q35131147-F2B58651-F375-403C-B89D-212FA6F74C00Q35248175-7007F4CB-6A40-4862-86AA-75277A11CF18Q35263848-EC6444F2-BC8B-4B57-87B1-6D8A6EEA2802Q35403712-17A30A17-6156-4012-8F70-4FEDDFCEE5D9Q35645650-A4C19089-B939-42A1-B8C2-4F87081D13EBQ35749402-D3A6B7AA-3078-48E1-977B-B43A2BA7254EQ35775223-77456CC0-DADC-46CA-A164-24C3F99B777AQ35930932-DE8D54CD-5241-45B3-BF01-EDF35CDB6B26Q36070055-81A48CFB-F5C5-4291-B43B-C7855ECB1FACQ36188973-454DBAC8-9B02-44BC-A2DF-CFB7B1D9308AQ36230861-9977B80F-D7EF-41FF-9768-F342111DFD78Q36279255-EB80CB99-C19C-4D87-8FDF-183160040961Q36304955-3DB63CD1-87F0-4129-B9A9-A21D32778EA5Q36360805-1D82BEDF-5733-43F0-92A9-9A498E7EED6BQ36372625-4BAA0AC2-2AD2-47D8-9D49-102DF4434D5FQ36461696-343FEBFE-AE1A-4A1C-B268-7FA85A57805CQ36494976-2B52D147-357F-452A-8E8B-BB262405022FQ36610578-360CF590-4B5D-46E0-938D-3DECC6EC9597
P2860
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cancer risks for male carriers ...... 2: a review of the literature.
@ast
Cancer risks for male carriers ...... 2: a review of the literature.
@en
Cancer risks for male carriers ...... 2: a review of the literature.
@nl
type
label
Cancer risks for male carriers ...... 2: a review of the literature.
@ast
Cancer risks for male carriers ...... 2: a review of the literature.
@en
Cancer risks for male carriers ...... 2: a review of the literature.
@nl
prefLabel
Cancer risks for male carriers ...... 2: a review of the literature.
@ast
Cancer risks for male carriers ...... 2: a review of the literature.
@en
Cancer risks for male carriers ...... 2: a review of the literature.
@nl
P356
P1476
Cancer risks for male carriers ...... 2: a review of the literature.
@en
P2093
Alexander Liede
Beth Y Karlan
P304
P356
10.1200/JCO.2004.05.055
P407
P577
2004-02-01T00:00:00Z